A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy

Lung Cancer

Volumn 37, Issue 1, 2002, Pages 73-77

  Sculier, J P ^a   Berghmans, T ^a   Lafitte, J J ^a   Richez, M ^a   Recloux, P ^a   Van Cutsem, O ^a   Ninane, V ^a   Mommen, P ^a   Paesmans, M ^a   Klastersky, J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Chemotherapy; Non small cell lung cancer; Paclitaxel

Indexed keywords

IFOSFAMIDE; PACLITAXEL; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TOLERANCE; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; REGISTRATION; SKIN INFECTION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING; CHEMICALLY INDUCED DISORDER; DRUG RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMAN; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGE; PACLITAXEL; POLYNEUROPATHIES; SURVIVAL; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0035985184     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00037-5     Document Type: Article

References (10)

1. Phase II and III studies with new drugs for non-small cell lung cancer: A systematic review of the literature with a methodology quality assessment
2. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
3. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
4. Paclitaxel by 1-hour infusion: An active drug in metastatic non-small-cell lung cancer
5. One-sample multiple testing procedure for phase II clinical trials
6. A phase II study testing a combination chemotherapy with epirubicin and vindesine as second line treatment for patients with advanced non-small cell lung cancer
7. A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party
8. Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: Report of a phase II trial
9. Second-line chemotherapy for recurrent non-small cell lung cancer: Do new agents make a difference?
10. Scoring systems in cancer patients admitted for an acute complication in a medical intensive care unit